Want to see STXS full AI Analyst Report?
Top Page
Stereotaxis
(STXS)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.50
▲(12.78% Upside)
Action:Reiterated
Date:08/18/26
The score is primarily constrained by weak financial performance—large ongoing losses and sustained negative operating/free cash flow—combined with a technically weak longer-term trend. Offsetting factors include a more constructive earnings outlook with concrete revenue guidance and a stated path to cash-flow profitability, plus strategic positioning supported by the Robocath acquisition, but execution (manufacturing ramp, system sales recovery) and financing/dilution risk remain central.
Positive Factors
Recurring Revenue Growth
Recurring revenue growth, led by robotically navigated catheters, can make the model more predictable and increase utilization of the installed base. Continued manufacturing expansion could support durable consumables growth and improve revenue quality.
Negative Factors
Persistent Losses and Cash Burn
Sustained operating losses and negative free cash flow show that the business is not yet self-funding. Continued cash burn could require external financing, constrain investment capacity and increase dilution risk before the targeted 2027 profitability milestone.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Revenue Growth
Recurring revenue growth, led by robotically navigated catheters, can make the model more predictable and increase utilization of the installed base. Continued manufacturing expansion could support durable consumables growth and improve revenue quality.
Read all positive factors
Stereotaxis (STXS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$138.28M
Dividend YieldN/A
Average Volume (3M)1.04M
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth-5.47%
EPS Growth13.55%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-0.25
Shares Outstanding100,202,180
10 Day Avg. Volume1,918,848
30 Day Avg. Volume1,043,755
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside125.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$39.40M
Stereotaxis Business Overview & Revenue Model
Company Description
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN...
How the Company Makes Money
Stereotaxis generates revenue primarily by selling and supporting its robotic magnetic navigation systems installed in hospitals and electrophysiology labs. A key recurring component of its model comes from procedure-driven sales of related consum...
Stereotaxis Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call contained multiple material positive operational and commercial milestones (FDA clearances, product launches, strong sequential and year‑over‑year growth in robotically navigated catheter revenue, Synchrony early sales, GenesisX installs and OEM compatibility progress, strategic Robocath acquisition) that point to an improving growth trajectory and a clear path to higher recurring revenue and margin expansion. Offsetting these positives are near‑term execution challenges: supply constraints for MAGiC catheters limiting sales, a YoY decline in system revenue driven by a missed system delivery, depressed system margins due to low volumes, ongoing operating losses and negative free cash flow, and transition‑related procedure pressure. Management provided concrete guidance and reiterated a plan to reach cash‑flow profitability in H1 2027, relying on manufacturing ramp and modest capital sales. Overall, the call indicates constructive commercial inflection and credible progress toward profitability, but with meaningful near‑term operational and financial risks that must be managed.Positive Updates
Recurring revenue momentum driven by robotically navigated catheters
Recurring revenue was $6.2M in Q2 2026 (CEO: recurring revenue surpassed $6M). Robotically navigated catheter revenue exceeded $1M in the quarter and the new catheter portfolio grew rapidly (company reported +270% sequentially and +450% year‑over‑year for robotically navigated catheters; CEO described nearly 300% sequential growth). Management expects ~+$1M incremental catheter revenue in each of the next couple quarters as manufacturing ramps.
Negative Updates
Year‑over‑year decline in system revenue and overall revenue headwind
System revenue declined to $1.5M in Q2 2026 from $3.0M in prior‑year Q2 (‑50% YoY). Overall revenue for the quarter declined YoY due to the lack of a robotic system delivery in the quarter.
Read all updates
Q2-2026 Updates
Positive
Negative
Recurring revenue momentum driven by robotically navigated catheters
Recurring revenue was $6.2M in Q2 2026 (CEO: recurring revenue surpassed $6M). Robotically navigated catheter revenue exceeded $1M in the quarter and the new catheter portfolio grew rapidly (company reported +270% sequentially and +450% year‑over‑year for robotically navigated catheters; CEO described nearly 300% sequential growth). Management expects ~+$1M incremental catheter revenue in each of the next couple quarters as manufacturing ramps.
Read all positive updates
Company Guidance
Management guided that recurring revenue—which was $6.2M of $7.7M total revenue in Q2 (robotic catheter revenue >$1M, up roughly 270–300% sequentially and ~450% YoY)—should rise to approximately $7M in Q3 and $8M in Q4, driven by an expected ~$1M incremental catheter revenue step‑up in each of the next couple quarters as manufacturing ramps (though sales remain supply‑constrained with a backlog). They expect system revenue to rebound from Q2’s $1.5M to about $3M in each of Q3 and Q4 (including recognition of one GenesisX sale in Q3) and see Synchrony supporting >$1M of system revenue per quarter near‑term (ASP ~ $200k). Q2 metrics included overall gross margin 58% (recurring 66%, systems 29%), operating loss $4.6M and net loss $4.5M (adjusted operating loss $2.1M, adjusted net loss $2.0M), operating expenses $9.1M (adjusted $6.6M), negative free cash flow $3.7M, and cash of $10.5M with no debt; management is modeling cash‑flow profitability in H1 2027 and expects recurring gross margins to expand toward the mid‑70s% in 2027–28.Stereotaxis Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.07M | 32.38M | 26.92M | 26.77M | 28.15M | 35.02M |
| Gross Profit | 16.71M | 17.07M | 14.59M | 14.86M | 18.47M | 23.23M |
| EBITDA | -21.13M | -20.09M | -23.08M | -20.12M | -17.86M | -10.60M |
| Net Income | -22.32M | -21.64M | -24.05M | -20.71M | -18.29M | -10.72M |
Balance Sheet | ||||||
| Total Assets | 55.58M | 52.25M | 46.72M | 41.91M | 53.41M | 60.98M |
| Cash, Cash Equivalents and Short-Term Investments | 10.49M | 13.42M | 12.22M | 19.82M | 28.43M | 38.74M |
| Total Debt | 5.17M | 5.44M | 6.01M | 5.49M | 5.86M | 6.11M |
| Total Liabilities | 38.10M | 33.53M | 35.29M | 19.99M | 21.48M | 21.56M |
| Stockholders Equity | 17.48M | 18.72M | 11.43M | 21.92M | 31.93M | 39.42M |
Cash Flow | ||||||
| Free Cash Flow | -15.50M | -13.78M | -8.53M | -9.51M | -10.79M | -4.34M |
| Operating Cash Flow | -15.29M | -13.69M | -8.50M | -9.14M | -8.41M | -2.95M |
| Investing Cash Flow | -1.29M | -93.00K | 74.00K | 19.77M | -22.09M | -1.40M |
| Financing Cash Flow | 20.11M | 14.76M | 297.00K | 81.00K | 220.00K | 547.00K |
Stereotaxis Technical Analysis
Negative
1.33
Price Trends
1.60
Negative
1.75
Negative
2.04
Negative
Market Momentum
-0.06
Negative
43.24
Neutral
42.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Negative. The current price of 1.33 is below the 20-day moving average (MA) of 1.38, below the 50-day MA of 1.60, and below the 200-day MA of 2.04, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 43.24 is Neutral, neither overbought nor oversold. The STOCH value of 42.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STXS.
Stereotaxis Risk Analysis
Stereotaxis disclosed 57 risk factors in its most recent earnings report. Stereotaxis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stereotaxis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $5.42B | 36.62 | 9.07% | ― | 10.51% | 20.67% | |
75 Outperform | $1.88B | 28.45 | 16.42% | 0.94% | 11.85% | 38.09% | |
69 Neutral | $2.25B | 210.98 | 2.14% | ― | 13.94% | ― | |
55 Neutral | $1.31B | 301.13 | 1.08% | ― | 51.30% | ― | |
55 Neutral | $43.93M | -10.23 | -149.08% | ― | 3.72% | 43.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $138.28M | -5.63 | -145.82% | ― | -5.47% | 13.55% |
* Healthcare Sector Average
STXS
Stereotaxis
1.39
-1.39
-50.00%
ATRC
Atricure
44.77
9.15
25.69%
LMAT
Lemaitre Vascular
82.51
-11.66
-12.38%
MMSI
Merit Medical Systems
89.73
3.57
4.14%
STAA
Staar Surgical
24.09
-3.90
-13.93%
MLSS
Milestone Scientific
0.49
-0.14
-22.66%
Stereotaxis Corporate Events
Business Operations and StrategyM&A Transactions
Stereotaxis Advances Vascular Robotics with Robocath Acquisition
Positive
Jul 9, 2026
On July 7, 2026, Stereotaxis completed its previously announced approximately $20 million acquisition of French vascular robotics company Robocath, issuing common shares and pre-funded warrants as consideration and as partial payment to Robocath&#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.